XellSmart

New Capabilities

Developer of XS411

Nine patients with moderate-to-advanced Parkinson's each received one injection of XS411 into both sides of the putamen, the brain region that degenerates in the disease. Six months later, average OFF-state motor scores had improved by more than 30 points on the MDS-UPDRS Part III scale, and patients gained over five hours of good ON time per day — time without troublesome involuntary movements. The results were presented October 18 at the International Congress of Parkinson's Disease and Movement Disorders, with no dose-limiting toxicities, serious adverse events or graft-induced dyskinesia reported.

Updated Oct 22